Merck & Co., Inc. (MRK)
144.30
+0.49
(+0.34%)
USD |
NYSE |
Oct 02, 16:00
144.30
0.00 (0.00%)
After-Hours: 20:00
Merck Enterprise Value : 403.00B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 403.00B |
| October 01, 2026 | 401.79B |
| September 30, 2026 | 405.49B |
| September 29, 2026 | 415.29B |
| September 28, 2026 | 413.84B |
| September 25, 2026 | 414.06B |
| September 24, 2026 | 412.08B |
| September 23, 2026 | 412.33B |
| September 22, 2026 | 419.32B |
| September 21, 2026 | 415.84B |
| September 18, 2026 | 409.34B |
| September 17, 2026 | 410.04B |
| September 16, 2026 | 404.51B |
| September 15, 2026 | 401.74B |
| September 14, 2026 | 404.36B |
| September 11, 2026 | 402.09B |
| September 10, 2026 | 404.01B |
| September 09, 2026 | 410.97B |
| September 08, 2026 | 413.27B |
| September 04, 2026 | 417.89B |
| September 03, 2026 | 422.85B |
| September 02, 2026 | 421.12B |
| September 01, 2026 | 416.73B |
| August 31, 2026 | 411.54B |
| August 28, 2026 | 413.00B |
| Date | Value |
|---|---|
| August 27, 2026 | 415.94B |
| August 26, 2026 | 424.72B |
| August 25, 2026 | 432.99B |
| August 24, 2026 | 418.70B |
| August 21, 2026 | 423.37B |
| August 20, 2026 | 414.58B |
| August 19, 2026 | 422.50B |
| August 18, 2026 | 380.46B |
| August 17, 2026 | 382.44B |
| August 14, 2026 | 382.12B |
| August 13, 2026 | 381.40B |
| August 12, 2026 | 374.91B |
| August 11, 2026 | 368.74B |
| August 10, 2026 | 369.97B |
| August 07, 2026 | 364.19B |
| August 06, 2026 | 363.67B |
| August 05, 2026 | 363.58B |
| August 04, 2026 | 362.76B |
| August 03, 2026 | 362.19B |
| July 31, 2026 | 368.19B |
| July 30, 2026 | 367.18B |
| July 29, 2026 | 368.59B |
| July 28, 2026 | 372.19B |
| July 27, 2026 | 369.57B |
| July 24, 2026 | 370.34B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Pfizer Inc. | 210.23B |
| Bristol Myers Squibb Co. | 158.92B |
| Viatris, Inc. | 32.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.337B |
| Revenue (Quarterly) | 16.58B |
| Total Expenses (Quarterly) | 17.92B |
| EPS Diluted (Quarterly) | -0.5405 |
| Gross Profit Margin (Quarterly) | 71.51% |
| Profit Margin (Quarterly) | -8.06% |
| Earnings Yield | 0.87% |
| Operating Earnings Yield | 3.48% |
| Normalized Earnings Yield | 2.096 |